Valuation: Insmed Incorporated

Market Cap 23.8B 20.81B 19.2B 17.65B 33.44B 2,290B 34.01B 229B 89.92B 1,119B 89.38B 87.43B 3,858B P/E 2026 *
-43.1x
P/E 2027 * 170x
Enterprise Value 23.24B 20.32B 18.74B 17.23B 32.64B 2,236B 33.2B 224B 87.79B 1,093B 87.26B 85.35B 3,767B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 8.24x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week-5.77%
Current month+2.99%
1 month+12.67%
3 months-25.17%
6 months-31.05%
Current year-36.91%
1 week 107.33
Extreme 107.33
118.94
1 month 94
Extreme 94
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
07-08Fiscal year

Chief Executive Officer

32,097 0.0148%
07-05Fiscal year

Chief Technology Officer

36,906 0.0170%
06-24Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-5.77%+6.75%+433.06% 23.8B
+3.13%+13.95%+64.21%+94.35% 57.82B
-1.39%-6.15%+56.05%+124.73% 53.71B
+1.76%-1.65%-16.86%-15.01% 23.26B
+2.18%+9.01%+48.53%-1.10% 20.7B
+1.94%+0.21%+39.31%-27.77% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.42%+10.21%+47.30%+701.07% 16.36B
-0.39%-1.00%+26.08%+186.49% 13.96B
+2.49%-2.68%+76.85%+143.72% 12.69B
Average +1.70%+1.01%+55.65%+201.05% 25.7B
Weighted average by Cap. +1.46%+1.15%+53.81%+170.27%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.37B 1.26B 2.38B 163B 2.43B 16.35B 6.41B 79.84B 6.38B 6.24B 275B 2.77B 2.42B 2.23B 2.05B 3.89B 267B 3.96B 26.68B 10.47B 130B 10.41B 10.18B 449B
Net income -560M -490M -452M -416M -787M -53.93B -801M -5.4B -2.12B -26.36B -2.1B -2.06B -90.85B 105M 91.42M 84.33M 77.52M 147M 10.06B 149M 1.01B 395M 4.92B 393M 384M 16.95B
Net Debt -566M -494M -456M -419M -794M -54.41B -808M -5.45B -2.14B -26.6B -2.12B -2.08B -91.67B -983M -860M -793M -729M -1.38B -94.6B -1.4B -9.47B -3.71B -46.24B -3.69B -3.61B -159B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-15 US$109.81 -0.27% 2,116,813
26-07-14 US$110.11 +0.89% 1,848,330
26-07-13 US$109.14 -5.60% 2,825,240
26-07-10 US$115.61 -2.24% 2,931,618
26-07-09 US$118.26 +1.48% 3,167,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
109.81USD
Average target price
196.38USD
Spread / Average Target
+78.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock